In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Asceneuron SA

Biotech Showcase 2019: Targeting Tau To Tackle Neurodegenerative Diseases

Asceneuron CEO Dirk Beher tells Mike Ward about the progress that the 2012 startup is making with its small-molecule therapeutics that reduce the accumulation of toxic aggregates of the tau protein into the neurofibrillary tangles.

Companies Research & Development

Where Will CNS Drug Development Go In 2018?

The world's expanding, aging population means diseases of the central nervous system, like Alzheimer's and Parkinson's, are potential blockbuster areas for innovative pharma and biotech companies that are able to navigate clinical studies and get to market. Scrip looks at five emerging trends that are likely to affect the CNS drug development landscape in 2018.

Neurology Business Strategies

Appointments: Promethera, HealthTell, Baxter, Alzheon, Gilead, Arena and Ligand

This week's appointment roundup includes senior appointments by Promethera, HealthTell, Alzheon and Gilead Nordic with Baxter International, Therachon and Arena Pharmaceuticals making board appointments.

Executive Changes

Appointments: IFPMA, Myokardia, ABPI, Mission Therapeutics, F2G, Arquer Diagnostics and Innovative Medicines Canada

This week's roundup includes top level updates from AstraZeneca and executive appointments by Myokardia, Asceneuron and Arquer Diagnostics.

Executive Changes BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register